Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pravitinib - Tactical Therapeutics

Next Previous
Search
Drug Profile

Pravitinib - Tactical Therapeutics

Alternative Names: CAI orotate; Carboxyamidotriazole orotate; CTO

Latest Information Update: 22 Feb 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tactical Therapeutics
  • Developer Duke University Medical Center; Tactical Therapeutics
  • Class Amides; Antineoplastics; Small molecules; Triazoles
  • Mechanism of Action Angiogenesis inhibitors; Bcr-Abl tyrosine kinase inhibitors; Calcium channel antagonists; Cyclo-oxygenase 2 inhibitors; Epidermal growth factor receptor antagonists; Growth inhibitors; Interleukin 2 inhibitors; Nitric oxide synthase type I inhibitors; Phosphotransferase inhibitors; Proto-oncogene protein c-akt inhibitors; Ras signal transduction pathway inhibitors; Vascular endothelial growth factor A expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Age-related macular degeneration; Colorectal cancer; Glioma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer

Most Recent Events

  • 22 Feb 2023 Discontinued - Phase-I for Colorectal cancer (Combination therapy, Metastatic disease) in USA (PO) (Tactical Therapeutics pipeline, February 2023)
  • 22 Feb 2023 Discontinued - Phase-I for Head and neck cancer in USA (PO) (Tactical Therapeutics pipeline, February 2023)
  • 22 Feb 2023 Discontinued - Phase-I for Non-small cell lung cancer (Combination therapy) in USA (PO) (Tactical Therapeutics pipeline, February 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top